Emerging drugs in endometrial cancers

Expert Opinion on Emerging Drugs

Volumn 15, Issue 4, 2010, Pages 557-568

  Altundag, Ozden ^a   Dursun, Polat ^a   Ayhan, Ali ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

chemotherapy; endometrial cancer; hormonal therapy; metastatic; targeted agents

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; GONADORELIN DERIVATIVE; HYDROXYPROGESTERONE; IXABEPILONE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MESTRANOL; NORETHISTERONE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PROGESTERONE; PROGESTERONE DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG RESEARCH; ENDOMETRIUM CANCER; FEMALE FERTILITY; HUMAN; METASTASIS; MONOTHERAPY; REVIEW;

ADENOCARCINOMA; ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; TREATMENT OUTCOME;

EID: 78649471700     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2010.517521     Document Type: Review

References (66)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
2. Dizon DS. Treatment options for advanced endometrial carcinoma. Gynecol Oncol 2010;117(2):373-81
3. Dellinger TH, Monk BJ. Systemic therapy for recurrent endometrial cancer: a review of North American trials. Expert Rev Anticancer Ther 2009;9(7):905-16
4. Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. Semin Oncol 2009;36:145-54
5. van Wijk FH, van der Burg ME, Burger CW, et al. Management of recurrent endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer 2009;19:314-20
6. Horton J, Begg CB, Arseneault J, et al. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 1978;62:159-61
7. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1408-14
8. Calero F, Asins-Codoner E, Jimeno J, et al. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO). Eur J Cancer 1991;27:864-6
9. Homesley HD, Blessing JA, Sorosky J, et al. Phase II evaluation of liposomal doxorubicin at 40 mg/m2 every 4 weeks in endometrial cancer: a GOG study. Gynecol Oncol 2005;98:294-8
10. Muggia F, Blessing J, Sorosky J, Reid G. Phase II trial of pegylayed liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002;20:2360-4
11. Seski JC, Edwards CL, Herson J, et al. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol 1982;59:225-8
12. Thigpen JT, Blessing JA, Homesley H, et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 1989;33:68-70
13. Long HJ, Pfeifle DM, Wieand HS, et al. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst 1988;80:276-8
14. Van Wijk FH, Lhomme C, Bolis G, et al. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 2003;39:78-85
15. Blessing JA, Lentz SS, Mutch DG. Phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996;62:278-81
16. Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88:277-81
17. Katsumata N, Noda K, Nozawa S, et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. Br J Cancer 2005;93:999-1004
18. Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007;25:2983-90 • This is the most comprehensive review about the standard chemotherapy in metastatic and adjuvant endometrial cancer.
19. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004;22(19):3902-38 • This randomized trial demonstrated a superior response rate with combination chemotherapy to doxorubicin alone.
20. Aapro MS, van Wijk FH, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003;14(3):441-8 • This randomized trial demonstrated a superior response rate with combination chemotherapy to doxorubicin alone.
21. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin - cisplatin versus doxorubicin - 24-h paclitaxel - filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 2004;15:1173-8
22. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159-66 • In this randomized trial three-drug combination arm produced superior response rate, progression-free and overall survival with increased toxicity. (Pubitemid 41095150)
23. Available from: http://clinicaltrials.gov/ct2/show/NCT00063999
24. Podczaski E, Mortel R. Hormonal treatment of endometrial cancer: past, present and future. Best Pract Res Clin Obstet Gynaecol 2001;15:469-89
25. Ramirez PT, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133-38
26. Eftekhar Z, Izadi-Mood N, Yarandi F, et al. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 2009;19:249-52
27. Kim YB, Holschneider CH, Ghosh K, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausalwomen. Report of seven cases and review of the literature. Cancer 1997;79:320-27
28. Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798-803
29. Gien L, Kwon J, Oliver TK, Fung-Kee-Fung M. Adjuvant hormonal therapy for stage I endometrial cancer. Curr Oncol 2008;15:126-35
30. Urbanski K, Karolewski K, Kojs Z, et al. Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one-institutional prospective clinical trial. Eur J Gynaecol Oncol 1993;14(Suppl): 98-104
31. Baker WH. Effects of 17-alpha-hydroxy progesterone caproate on metastatic endometrial cancer. Conference on experimental clinical cancer chemotherapy, Monograph; 9, National Cancer Institute, Bethesda, Maryland; 1960. p. 235-41
32. Piver MS, Barlow JJ, Lurain JR, Blumenson LE. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 1980;45:268-72
33. Podratz KC, O'Brien PC, Malkasian GD, et al. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985;66:106-10
34. Thigpen T, Blessing J, DiSaia P, Ehrlich C. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: results of therapy and correlation with estrogen and progesterone receptor levels. The Gynecologic Oncology Group experience. In: Baulieo EE, Lacobelli S, McGuire WL, editors Endocrinology and malignancy: basic and clinical issues, Parthenon Publishing Group, Park Ridge, New Jersey; 1986. p. 446-54
35. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007;17:964-78
36. Garrett A. Quinn MA. Hormonal therapies and gynaecological cancers. Best Pract Res Clin Obstet Gynaecol 2008;22:407-21
37. Ferguson G, Herzog T. Current research on the use of hormonal therapy in the treatment of advanced or recurrent endometrial cancer. Womens Oncol Rev 2004;4:175-80
38. Jeyarajah AR, Gallagher CJ, Blake PR, et al. Long-term follow up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol 1996;63:47-52
39. Asbury RF, Brunetto VL, Lee RB, et al. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 2002;25:557-60
40. Bilbao C, Rodriguez G, Ramirez R, et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer 2006;119:563-70
41. Oza AM, Elit L, Biagi J, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160. J Clin Oncol 2006;24(18 S): 3003
42. Oza AM, Elit L, Provencher D, et al. "A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol 2008;26(20 S): 5516
43. Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 2007;25(18 S): 5516
44. Grushko TA, Filiaci VL, Mundt AJ, et al. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008;108:3-9
45. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51
46. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:15-20
47. Niikura H, Sasano H, Matsunaga G, et al. Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. Hum Pathol 1995;26:892-6
48. Khalifa MA, Mannel RS, Haraway SD, et al. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994;53:84-92
49. Scambia G, Benedetti Panici P, Ferrandina G, et al. Significance of epidermal growth factor receptor expression in primary human endometrial cancer. Int J Cancer 1994;56:26-30
50. Baguley BC, Marshall ES, Holdaway KM, et al. Inhibition of growth of primary human tumor cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. Eur J Cancer 1998;34:1086-90
51. Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26:4319-25
52. Leslie KK, Sill MW, Darcy KM, et al. Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. J Clin Oncol 2009;27(15 S): e16542
53. Available from: http://clinicaltrials.gov/ct2/show/NCT00392769
54. Mazurek A, Telego M, Pierzynski P, et al. Angiogenesis in endometrial cancer. Neoplasma 1998;45:360-4
55. Yokoyama Y, Charnock-Jones DS, Licence D, et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 2003;9:1361-9
56. Aghajanian C, Sill MW, Darcy K, et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) Study. J Clin Oncol 2009;27(15 S): 5531
57. McMeekin DS, Sill MW, Benbrook D, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 2007;105:508-16 (Pubitemid 46591977)
58. Available from: http://clinicaltrials.gov/ct2/show/NCT00301964
59. Available from: http://clinicaltrials.gov/ct2/show/NCT00462826
60. Ninomiya Y, Kato K, Takahashi A, et al. K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival. Cancer Res 2004;64:2759-65
61. Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007;13:7487-95
62. Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010;117(1):37-40
63. Miller DS, Blessing JA, Drake RD, et al. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol 2009;115:443-6
64. Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol 2009;27:3104-8
65. NCT00977574 study synopsis. Paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab in treating patients with Stage III, Stage IV, or recurrent endometrial cancer. Updated February 1, 2010. Available from: http://clinicaltrials. gov [Accessed 2 February 2010]
66. NCT00883116 study synopsis. A phase III, open-label, randomized, 2 arm study of ixabepilone administered every 21 days versus paclitaxel or doxorubicin administered every 21 days in women with advanced endometrial cancer who have previously been treated with chemotherapy. Updated 17 June 2009. Available from: http://clinicaltrials. gov [Accessed 2 February 2010]